Die rasante Entwicklung der Diabetesforschung hat viele neue Medikamente und Therapiestrategien
auf den Weg gebracht, die das Potenzial haben, auch unabhängig von einer Diabeteserkrankung
wirksam zu sein. So gibt es neue Erkenntnisse zu SGLT-2-Inhibitoren bei Herz- und
chronischer Niereninsuffizienz. Auch die Weiterentwicklung inkretinbasierter Medikamente
und duale GIP/GLP-1-Rezeptoragonisten sind vielversprechend.
Abstract
Diabetes mellitus has become a widespread disease worldwide. In recent years, there
has been a rapid development of therapeutic options in the field of diabetology. Many
new drugs and therapeutic strategies are now available or will be available in the
near future, which have the potential to significantly improve the care of patients
even if they do not have diabetes. In this article, we would like to present the latest
therapeutic options and possible further applications. The article focuses, among
other things, on the new findings of SGLT-2-inhibitors in cardiac and chronic renal
failure and the further development of incretin-based drugs toward dual GIP/GLP-1-receptor
agonists. Once-weekly insulin and the selective mineralocorticoid receptor antagonist
finerenone will also be presented.
Schlüsselwörter
Diabetes mellitus Typ 2 - GLP-1- Rezeptoragonisten - SGLT-2-Inhibitoren - Insulin
Icodec - Finerenon
Key words
type 2 diabetes mellitus - GLP-1 receptor agonist - SGLT-2-inhibitors - insulin icodec
- finerenone
